Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine …
F Novak, HM Bajwa, JE Coia, AC Nilsson… - Journal of Neurology …, 2023 - jnnp.bmj.com
Background Our study investigated the rate of breakthrough SARS-CoV-2 infection and
clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the …
clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the …
Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine …
F Novak, HM Bajwa, JE Coia… - Journal of …, 2023 - portal.findresearcher.sdu.dk
BACKGROUND: Our study investigated the rate of breakthrough SARS-CoV-2 infection and
clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the …
clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the …
[HTML][HTML] Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA …
F Novak, HM Bajwa, JE Coia, AC Nilsson… - Journal of Neurology …, 2023 - ncbi.nlm.nih.gov
Background Our study investigated the rate of breakthrough SARS-CoV-2 infection and
clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the …
clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the …
[PDF][PDF] Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA …
F Novak, HM Bajwa, JE Coia, AC Nilsson, C Nielsen… - scienceopen.com
Background Our study investigated the rate of breakthrough SARS-CoV-2 infection and
clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the …
clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the …
Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine …
F Novak, HM Bajwa, JE Coia… - Journal of …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Our study investigated the rate of breakthrough SARS-CoV-2 infection and
clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the …
clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the …
[PDF][PDF] Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA …
F Novak, HM Bajwa, JE Coia, AC Nilsson, C Nielsen… - researchgate.net
Background Our study investigated the rate of breakthrough SARS-CoV-2 infection and
clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the …
clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the …
Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine …
F Novak, HM Bajwa, JE Coia… - Journal of …, 2023 - search.proquest.com
Background Our study investigated the rate of breakthrough SARS-CoV-2 infection and
clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the …
clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the …
Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine …
F Novak, HM Bajwa, JE Coia, AC Nilsson, C Nielsen… - 2023 - escholarship.org
BackgroundOur study investigated the rate of breakthrough SARS-CoV-2 infection and
clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the …
clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the …
[PDF][PDF] Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA …
F Novak, HM Bajwa, JE Coia, AC Nilsson… - Journal of Neurology …, 2023 - jnnp.bmj.com
Background Our study investigated the rate of breakthrough SARS-CoV-2 infection and
clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the …
clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the …
Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine …
F Novak, HM Bajwa, JE Coia… - Journal of neurology …, 2023 - research.regionh.dk
BACKGROUND: Our study investigated the rate of breakthrough SARS-CoV-2 infection and
clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the …
clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the …